Affiliation:
1. Departments of Dermatology and Venereology, All India Institute of Medical Sciences , New Delhi , India
Abstract
A few studies have looked at the efficacy of tofacitinib in severe alopecia areata (AA), characterized by ≥ 50% scalp hair loss. Here, we aimed to assess retrospective data for the role of tofacitinib as an induction agent in severe AA, compared with the standard oral mini-pulse (OMP). Tofacitinib holds promise as an induction agent for patients with severe AA, comparable with OMP. However, when patients respond inadequately to tofacitinib, a trial of pulse steroids may be considered.
Publisher
Oxford University Press (OUP)
Reference7 articles.
1. Defining severity in alopecia areata: current perspectives and a multidimensional framework;King;Dermatol Ther (Heidelb,2022
2. Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: a retrospective study;Shin;Acta Derm Venereol,2018
3. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients;Liu;J Am Acad Dermatol,2017
4. Extensive alopecia areata treated with betamethasone oral mini-pulse therapy: an open uncontrolled study;Khaitan;Indian J Dermatol Venereol Leprol,2004
5. Oral tofacitinib and systemic corticosteroids, alone or in combination, in patients with moderate-to-severe alopecia areata: a retrospective study;Zhang;Front Med,2022